ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$6.46 USD
-0.08 (-1.22%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $6.46 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum C VGM
Brokerage Reports
0 items in cart
ADMA Biologics Inc [ADMA]
Reports for Purchase
Showing records 41 - 60 ( 72 total )
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
BIVIGAM Market Re-Entry Authorized; Cash Replenished; Multiple Near-Term Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
BIVIGAM Market Re-Entry Authorized; Cash Replenished; Multiple Near-Term Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Credit Agreement Draw-Down Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
ASCENIV Approval Granted; Raising Target to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
FY2018 Financial Results Reported; Awaiting FDA Response on BIVIGAM; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
New Credit Agreement Implemented; Less Onerous Debt Terms; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Slowly but Surely Making a Comeback; Assuming Coverage at Buy and $10 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
All Systems Are Go as ADMA Reports 3Q18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Initiating Coverage With a Buy Rating and $17 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J